# Smith Micro Software, Inc.: financial statements, quarterly

SMSI · Nasdaq · CIK 948708 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/smsi.md) · [Financials](/companies/smsi/financials.md) · [Filings](/companies/smsi/filings.md) · [Insiders](/companies/smsi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/smsi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [11.0](/filings/0000948708-24-000035.md) | [8.6 d](/filings/0000948708-25-000004.md) | [5.8](/filings/0000948708-25-000010.md) | [5.1](/filings/0001437749-25-025451.md) | [4.6](/filings/0001437749-25-033340.md) | [5.0 d](/filings/0001437749-26-007087.md) | [4.6](/filings/0001437749-26-014454.md) | [4.4](/filings/0001437749-26-027989.md) | [4.3](/filings/0001437749-25-033340.md) | [4.0 d](/filings/0001437749-26-007087.md) | [4.2](/filings/0001437749-26-014454.md) | [4.3](/filings/0001437749-26-027989.md) |
| Cost of revenue | $m | [2.5](/filings/0000948708-24-000035.md) | [2.2 d](/filings/0000948708-25-000004.md) | [2.0](/filings/0000948708-25-000010.md) | [1.6](/filings/0001437749-25-025451.md) | [1.3](/filings/0001437749-25-033340.md) | [1.2 d](/filings/0001437749-26-007087.md) | [1.3](/filings/0001437749-26-014454.md) | [1.2](/filings/0001437749-26-027989.md) | [1.1](/filings/0001437749-25-033340.md) | [0.9 d](/filings/0001437749-26-007087.md) | [0.9](/filings/0001437749-26-014454.md) | [0.8](/filings/0001437749-26-027989.md) |
| Gross profit | $m | [8.5](/filings/0000948708-24-000035.md) | [6.4 d](/filings/0000948708-25-000004.md) | [3.8](/filings/0000948708-25-000010.md) | [3.5](/filings/0001437749-25-025451.md) | [3.3](/filings/0001437749-25-033340.md) | [3.8 d](/filings/0001437749-26-007087.md) | [3.4](/filings/0001437749-26-014454.md) | [3.2](/filings/0001437749-26-027989.md) | [3.2](/filings/0001437749-25-033340.md) | [3.0 d](/filings/0001437749-26-007087.md) | [3.3](/filings/0001437749-26-014454.md) | [3.5](/filings/0001437749-26-027989.md) |
| Research and development | $m | [3.7](/filings/0000948708-24-000035.md) | [3.9 d](/filings/0000948708-25-000004.md) | [4.0](/filings/0000948708-25-000010.md) | [3.7](/filings/0001437749-25-025451.md) | [3.6](/filings/0001437749-25-033340.md) | [2.8 d](/filings/0001437749-26-007087.md) | [2.9](/filings/0001437749-26-014454.md) | [2.8](/filings/0001437749-26-027989.md) | [2.6](/filings/0001437749-25-033340.md) | [2.5 d](/filings/0001437749-26-007087.md) | [1.8](/filings/0001437749-26-014454.md) | [1.4](/filings/0001437749-26-027989.md) |
| Operating income | $m | [(2.2)](/filings/0000948708-24-000035.md) | [(5.7) d](/filings/0000948708-25-000004.md) | [(31.4)](/filings/0000948708-25-000010.md) | [(7.0)](/filings/0001437749-25-025451.md) | [(6.5)](/filings/0001437749-25-033340.md) | [(4.5) d](/filings/0001437749-26-007087.md) | [(5.2)](/filings/0001437749-26-014454.md) | [(15.0)](/filings/0001437749-26-027989.md) | [(4.5)](/filings/0001437749-25-033340.md) | [(4.4) d](/filings/0001437749-26-007087.md) | [(3.4)](/filings/0001437749-26-014454.md) | [(2.4)](/filings/0001437749-26-027989.md) |
| Interest expense | $m | not reported | not reported | not reported | [(0.0)](/filings/0001437749-25-025451.md) | [0.0](/filings/0001437749-25-033340.md) | [(0.0) d](/filings/0001437749-26-007087.md) | [0.0](/filings/0001437749-26-014454.md) | [0.0](/filings/0001437749-26-027989.md) | [0.1](/filings/0001437749-25-033340.md) | [0.3 d](/filings/0001437749-26-007087.md) | [0.5](/filings/0001437749-26-014454.md) | [0.2](/filings/0001437749-26-027989.md) |
| Income tax | $m | [0.0](/filings/0000948708-24-000035.md) | [0.1 d](/filings/0000948708-25-000004.md) | [0.0](/filings/0000948708-25-000010.md) | [0.0](/filings/0001437749-25-025451.md) | [0.0](/filings/0001437749-25-033340.md) | [(0.1) d](/filings/0001437749-26-007087.md) | [0.0](/filings/0001437749-26-014454.md) | [0.0](/filings/0001437749-26-027989.md) | [0.0](/filings/0001437749-25-033340.md) | [(0.1) d](/filings/0001437749-26-007087.md) | [0.0](/filings/0001437749-26-014454.md) | [0.0](/filings/0001437749-26-027989.md) |
| Net income | $m | [(5.1)](/filings/0000948708-24-000035.md) | [(6.7) d](/filings/0000948708-25-000004.md) | [(31.0)](/filings/0000948708-25-000010.md) | [(6.9)](/filings/0001437749-25-025451.md) | [(6.4)](/filings/0001437749-25-033340.md) | [(4.4) d](/filings/0001437749-26-007087.md) | [(5.2)](/filings/0001437749-26-014454.md) | [(15.1)](/filings/0001437749-26-027989.md) | [(4.5)](/filings/0001437749-25-033340.md) | [(4.6) d](/filings/0001437749-26-007087.md) | [(3.9)](/filings/0001437749-26-014454.md) | [(2.6)](/filings/0001437749-26-027989.md) |
| Diluted EPS | $ per share | [(0.61)](/filings/0000948708-24-000035.md) | not reported | [(3.28)](/filings/0000948708-25-000010.md) | [(0.66)](/filings/0001437749-25-025451.md) | [(0.54)](/filings/0001437749-25-033340.md) | not reported | [(0.28)](/filings/0001437749-26-014454.md) | [(3.88)](/filings/0001437749-26-027989.md) | [(0.25)](/filings/0001437749-25-033340.md) | not reported | [(0.15)](/filings/0001437749-26-014454.md) | [(0.52)](/filings/0001437749-26-027989.md) |
| Basic EPS | $ per share | [(0.61)](/filings/0000948708-24-000035.md) | not reported | [(3.28)](/filings/0000948708-25-000010.md) | [(0.66)](/filings/0001437749-25-025451.md) | [(0.54)](/filings/0001437749-25-033340.md) | not reported | [(0.28)](/filings/0001437749-26-014454.md) | [(3.88)](/filings/0001437749-26-027989.md) | [(0.25)](/filings/0001437749-25-033340.md) | not reported | [(0.15)](/filings/0001437749-26-014454.md) | [(0.52)](/filings/0001437749-26-027989.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold, us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [8.0](/filings/0000948708-23-000037.md) | [7.1](/filings/0000948708-25-000004.md) | [6.2](/filings/0000948708-24-000020.md) | [5.6](/filings/0000948708-24-000026.md) | [1.5](/filings/0000948708-24-000035.md) | [2.8](/filings/0001437749-26-007087.md) | [2.3](/filings/0000948708-25-000010.md) | [1.4](/filings/0001437749-25-025451.md) | [1.4](/filings/0001437749-25-033340.md) | [1.5](/filings/0001437749-26-027989.md) | [1.7](/filings/0001437749-26-014454.md) | [2.8](/filings/0001437749-26-027989.md) |
| Current assets | $m | [21.2](/filings/0000948708-23-000037.md) | [16.9](/filings/0000948708-25-000004.md) | [12.3](/filings/0000948708-24-000020.md) | [11.5](/filings/0000948708-24-000026.md) | [6.4](/filings/0000948708-24-000035.md) | [10.0](/filings/0001437749-26-007087.md) | [7.0](/filings/0000948708-25-000010.md) | [5.9](/filings/0001437749-25-025451.md) | [5.1](/filings/0001437749-25-033340.md) | [4.5](/filings/0001437749-26-027989.md) | [6.0](/filings/0001437749-26-014454.md) | [6.8](/filings/0001437749-26-027989.md) |
| Total assets | $m | [92.3](/filings/0000948708-23-000037.md) | [85.6](/filings/0000948708-25-000004.md) | [55.4](/filings/0000948708-24-000020.md) | [53.0](/filings/0000948708-24-000026.md) | [46.2](/filings/0000948708-24-000035.md) | [48.0](/filings/0001437749-26-007087.md) | [43.4](/filings/0000948708-25-000010.md) | [29.6](/filings/0001437749-25-025451.md) | [27.1](/filings/0001437749-25-033340.md) | [25.0](/filings/0001437749-26-027989.md) | [25.8](/filings/0001437749-26-014454.md) | [25.9](/filings/0001437749-26-027989.md) |
| Current liabilities | $m | [12.2](/filings/0000948708-23-000037.md) | [7.6](/filings/0000948708-25-000004.md) | [7.2](/filings/0000948708-24-000020.md) | [7.5](/filings/0000948708-24-000026.md) | [6.4](/filings/0000948708-24-000035.md) | [5.7](/filings/0001437749-26-007087.md) | [5.7](/filings/0000948708-25-000010.md) | [6.3](/filings/0001437749-25-025451.md) | [6.5](/filings/0001437749-25-033340.md) | [6.1](/filings/0001437749-26-027989.md) | [4.4](/filings/0001437749-26-014454.md) | [4.7](/filings/0001437749-26-027989.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [76.9](/filings/0000948708-24-000035.md) | [75.4](/filings/0001437749-26-007087.md) | [45.4](/filings/0001437749-25-025451.md) | [42.9](/filings/0001437749-25-033340.md) | [37.7](/filings/0001437749-25-033340.md) | [40.8](/filings/0001437749-26-027989.md) | [36.6](/filings/0001437749-26-027989.md) | [22.4](/filings/0001437749-26-027989.md) | [19.9](/filings/0001437749-25-033340.md) | [18.4](/filings/0001437749-26-027989.md) | [18.3](/filings/0001437749-26-027989.md) | [17.3](/filings/0001437749-26-027989.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [1,541 d](/filings/0000948708-24-000035.md) | [(1,023) d](/filings/0000948708-25-000004.md) | [(1,345)](/filings/0000948708-25-000010.md) | [(4,208) d](/filings/0001437749-25-025451.md) | [(3,815) d](/filings/0001437749-25-033340.md) | [(4,927) d](/filings/0001437749-26-007087.md) | [(602)](/filings/0001437749-26-014454.md) | [(2,268) d](/filings/0001437749-26-027989.md) | [(2,137) d](/filings/0001437749-25-033340.md) | [(2,186) d](/filings/0001437749-26-007087.md) | [(3,752)](/filings/0001437749-26-014454.md) | [(882) d](/filings/0001437749-26-027989.md) |
| Capital expenditure | $k | not reported | [(1.0) d](/filings/0000948708-25-000004.md) | [4.0](/filings/0000948708-25-000010.md) | [7.0 d](/filings/0001437749-25-025451.md) | [6.0 d](/filings/0001437749-25-033340.md) | [3.0 d](/filings/0001437749-26-007087.md) | [4.0](/filings/0001437749-26-014454.md) | [27.0 d](/filings/0001437749-26-027989.md) | [21.0 d](/filings/0001437749-25-033340.md) | [36.0 d](/filings/0001437749-26-007087.md) | [11.0](/filings/0001437749-26-014454.md) | [61.0 d](/filings/0001437749-26-027989.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets, us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [55.7](/filings/0000948708-23-000037.md) | [7.1](/filings/0000948708-24-000020.md) | [7.8](/filings/0000948708-24-000026.md) | [8.4](/filings/0000948708-24-000035.md) | [9.5](/filings/0000948708-25-000010.md) | [10.6](/filings/0001437749-25-025451.md) | [11.8](/filings/0001437749-25-033340.md) | [18.2](/filings/0001437749-26-014454.md) | [3.9](/filings/0001437749-26-027989.md) | [21.0](/filings/0001437749-25-033340.md) | [25.7](/filings/0001437749-26-014454.md) | [5.2](/filings/0001437749-26-027989.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 5,589,880 at 2026-08-12, from the cover of the [10-Q filed 2026-08-14](/filings/0001437749-26-027989.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.